drugset
Drugs / BRECANAVIR
last change Jun 2007 re-read 2 minutes ago

BRECANAVIR

also known as GW640385 · GW-640385X · GW-64085X

Small molecule

Developed for
HIV infectious disease
Investigated by
ViiV Healthcare

Trials 2 · a red edge is where a trial was stopped

today NCT00242879 · Ph 2 NCT00257621 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00242879 Aug 2005 → Jun 2007 HIV infectious disease ViiV Healthcare Terminated No outcome recorded
Phase 2 NCT00257621 Oct 2004 → Jan 2007 HIV infectious disease ViiV Healthcare Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2005-12-16 Vertex Pharmaceuticals Incorporated GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir vrtx.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BRECANAVIR ChEMBL registry synonym — accepted as the source's own label CHEMBL206031 ↗
Known as GW-640385X ChEMBL registry synonym — accepted as the source's own label CHEMBL206031 ↗
Known as GW-64085X ChEMBL registry synonym — accepted as the source's own label CHEMBL206031 ↗
Known as GW640385 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00242879 ↗
1

NCT00257621 ↗
Action Inhibit “GW640385, a protease inhibitor” NCT00257621 ↗
Modality Small molecule — CHEMBL206031 ↗